AdAlta
next generation protein therapeutics

ASX Announcement

AdAlta shareholder information sessions

MELBOURNE Australia, 18th April, 2018: AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to invite shareholders to attend information briefing sessions to discuss the significant improvement to its lead therapeutic program AD-214.

Shareholder briefing sessions:

The following sessions are available to those shareholders able to attend:

Melbourne:	Monday, 23rd April, 10:00am CSBC: Level 14, 330 Collins Street, Melbourne
Brisbane:	Tuesday 24th April, 10:00am Bentleys Queensland: Level 9, 123 Albert Street Brisbane QLD 4000
Perth:	Thursday 26th April, 11:00 am Patersons Stockbroking: Level 23, Exchange Tower, 2 The Esplanade, Perth
Sydney:	Monday, 30th April, 10:00 am FB Rice: Level 23, 44 Market Street, Sydney

Please RSVP to attend

Shareholders wishing to register interest in attending one of the events outlined below should RSVP by phoning Ebony Fietz on +61 0409 018 525 or by using the Contact Us form on the AdAlta website at http://adalta.com.au/contact-us/ or emailing enquiries@adalta.com.au. At the time of RSVP, please note your: name, email, contact number and which briefing session is of interest (Sydney, Melbourne, Brisbane or Perth.)

The AdAlta team looks forward to seeing those shareholders who are able to attend.

Notes to Editors

About AdAlta

AdAlta Limited is an Australian based drug development company headquartered in Melbourne. The Company is focused on using its proprietary technology platform to generate i-bodies, a new class of protein therapeutics, with applications as therapeutic drugs to treat disease.

I-bodies are a promising, novel class of drugs that offer a new and more effective approach to treating a wide range of human diseases. They are identified and developed using our proprietary technology platform.

We have pioneered a technology that mimics the shape and stability of a crucial antigen-binding domain, that was discovered initially in sharks and then developed as a human protein. The result is a range of unique compounds, now known as i-bodies, for use in treating serious diseases.

AdAlta is developing its lead i-body candidate, AD-214, for the treatment of idiopathic pulmonary fibrosis (IPF) and other human fibrotic diseases, for which current therapies are sub-optimal and there is a high-unmet medical need.

The Company also plans to continue further drug discovery and development directed towards other drug targets and diseases with its i-body technology platform.

Further information can be found at: www.adalta.com.au.

For more information, please contact:

AdAlta Limited
Sam Cobb, CEO
Tel: +61 (0)3 9479 5159
E: s.cobb@adalta.com.au